Eidos Therapeutics Inc EIDX:NASDAQ

Last Price$36.55NASDAQ Closing Price as of 4:00PM ET 7/23/19

Today's Change+0.02(0.05%)
Bid (Size)$36.54 (2)
Ask (Size)$36.69 (18)
Day Low / High$35.29 - 36.85
Volume146.7 K
 

View Biotechnology IndustryPeer Comparison as of 07/23/2019

 

Eidos Therapeutics Inc ( NASDAQ )

Price: $36.55
Change: +0.02 (0.05%)
Volume: 146.7 K
4:00PM ET 7/23/2019
 
 

Sangamo Therapeutics Inc ( NASDAQ )

Price: $11.89
Change: +0.05 (0.42%)
Volume: 884.3 K
4:00PM ET 7/23/2019
 
 

Alector Inc ( NASDAQ )

Price: $19.24
Change: +0.33 (1.75%)
Volume: 87.5 K
4:00PM ET 7/23/2019
 
 

OPKO Health Inc ( NASDAQ )

Price: $2.08
Change: +0.01 (0.48%)
Volume: 2.3 M
4:00PM ET 7/23/2019
 
 

Heron Therapeutics Inc ( NASDAQ )

Price: $17.82
Change: -0.36 (1.98%)
Volume: 632.0 K
4:00PM ET 7/23/2019
 

Read more news Recent News

--Analyst Actions: Piper Jaffray Initiates Eidos Therapeutics at Overweight, Sets $55 PT
9:13AM ET 7/22/2019 MT Newswires

Price: 34.85, Change: -1.48, Percent Change: -4.07 ...

Insider Trends: Insider Purchase Adds to Eidos Therapeutics Positive Trend
9:34PM ET 7/08/2019 MT Newswires

Dr Neil Kumar, 10% Owner, Director and CEO, bought 882,353 shares in Eidos Therapeutics (EIDX) on Jul 03, 2019, for $26,382,796. Following the Form 4...

Insider Trends: 90-Day Buying Trend Extended with Insider Purchase of Eidos Therapeutics Stock
9:34PM ET 7/08/2019 MT Newswires

On Jul 03, 2019, Ali J Satvat, 10% Owner and Director, reported a purchase of 882,353 shares in Eidos Therapeutics (EIDX) for $26,382,796. After the Form...

Insider Trends: 90-Day Buying Trend Extended with Insider Purchase of Eidos Therapeutics Stock
9:31PM ET 7/08/2019 MT Newswires

Dr Eric Aguiar, 10% Owner and Director, executed a purchase for 882,353 shares of Eidos Therapeutics (EIDX) on Jul 03, 2019, for $26,382,796. After the...

Company Profile

Business DescriptionEidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA. View company web site for more details
Address101 Montgomery Street
San Francisco, California 94101
Phone+1.415.887.1471
Number of Employees24
Recent SEC Filing07/17/20194
Chief Executive Officer & DirectorNeil Kumar
President & Chief Medical OfficerJonathan Fox
CFO & Principal Accounting OfficerChristine E. Siu
Chief Scientific OfficerUma Sinha

Company Highlights

Price Open$36.76
Previous Close$36.53
52 Week Range$8.89 - 41.35
Market Capitalization$1.3 B
Shares Outstanding36.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/06/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.18
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-26.62%

Analyst Ratings as of 07/12/2019

Buy
5
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset